Perrigo Q1 net sales fall 7.2% to $969 million; $330.8 million impairment drives loss
Perrigo reported first-quarter 2026 results from continuing operations, with reported net sales down 7.2% to $969 million and a $330.8 million goodwill impairment charge that drove a reported diluted loss per share of $(2.81). Adjusted All In diluted EPS fell 28.3% to $0.43, and the company maintained its full-year 2026 outlook, including adjusted EPS guidance of $2.00 to $2.30 on an All In basis, while completing the Dermacosmetics sale after quarter end.
Key points
- Reported net sales were $969 million, down 7.2% year over year; Core net sales were $842 million, down 8.3%.
- Reported diluted EPS was $(2.81) for continuing operations, primarily due to the $330.8 million goodwill impairment charge.
- Adjusted All In diluted EPS was $0.43, down 28.3%; Core adjusted diluted EPS was $0.40, down 20.0%.
- The company maintained its 2026 outlook, with All In adjusted EPS guidance of $2.00 to $2.30, and completed the Dermacosmetics sale for €305.6 million in upfront cash after quarter end.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.